个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Drug-coated balloon for the treatment of small vessel disease: 9 months of angiographic results and 12 months of clinical outcomes of the PEPCAD China SVD study

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Qian Juying[1,2] * ; Wu Yizhe[1,2] * ; Li Chenguang[1,2] ; Yin Jiasheng[1,2] ; Fu Guosheng[3] ; Wang Jian'an[4] ; He Yong[5] ; Ma Genshan[6] ; Chen Yundai[7] ; Xia Yong[8] ; Li Lang[9] ; Ji Fusui[10] ; Zeng Hesong[11] ; Wei Meng[12] ; Nie Shaoping[13] ; Jin Huigen[14] ; He Ben[15] ; Chen Yuguo[16] ; Liu Fan[17] ; Wang Hui[18] ; Sun Yingxian[19] ; Xu Bo[20] ; Ge Junbo[1,2,*1] ;
单位： [1]Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China. [2]National Clinical Research Center for Interventional Medicine, Shanghai, China. [3]Department of Cardiology, Sir Run Run Shaw Hospital, Zhenjiang University School of Medicine, Hangzhou, China. [4]Department of Cardiology, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China. [5]Department of Cardiology, West China Hospital of Sichuan University, Chengdu, China. [6]Department of Cardiology, Zhongda Hospital Southeast University, Nanjing, China. [7]Department of Cardiology, Chinese PLA General Hospital, Beijing, China. [8]Department of Cardiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. [9]Department of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. [10]Department of Cardiology, Beijing Hospital of the Ministry of Health, Beijing, China. [11]Department of Cardiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. [12]Department of Cardiology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai, China. [13]Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. [14]Department of Cardiology, Central Hospital of Putuo District, Shanghai, China. [15]Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China. [16]Department of Cardiology, Qilu Hospital of Shandong University, Ji'nan, China. [17]Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, China. [18]Department of Cardiology, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China. [19]Department of Cardiology, The First Hospital of China Medical University, Shenyang, China. [20]Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Beijing, China.
出处：
DOI： 10.1002/ccd.30472
ISSN：

关键词： coronary artery disease drug‐coated balloon percutaneous coronary intervention small vessel disease

摘要：
Whether the drug-coated balloons (DCBs)-alone strategy was superior to plain old balloon angioplasty (POBA) in treating SVD remains unknown.We aimed to evaluate the efficacy and safety of DCBs for the treatment of coronary de novo small vessel disease (SVD) and provide further evidence for extending the clinical indications of DCBs. (ChiCTR1800014966).Eligible patients were randomized at a 2:1 ratio to receive DCB treatment or POBA in this prospective, multicenter clinical trial. The reference vessel diameter of lesions was visually assessed to be 2.0 to 2.75 mm. The primary endpoint of the study was angiographic in-segment late luminal loss (LLL) at the 9-month follow-up to demonstrate the superiority of DCB treatment to POBA in SVD. The composite clinical endpoints included clinically driven target lesion revascularization (CD-TLR), target lesion failure (TLF), major adverse cardiac events (MACEs), and thrombosis at the 12-month follow-up.A total of 270 patients were enrolled (181 for DCB, 89 for POBA) at 18 centers in China. The primary endpoint of 9-month in-segment LLL in the intention-to-treat population was 0.10 ± 0.33 mm with DCB and 0.25 ± 0.38 mm with POBA (p = 0.0027). This difference indicated significant superiority of DCB treatment (95% CI: -0.22, -0.04, psuperiority  = 0.0068). The rates of the clinical endpoints-CD-TLR, TLF, and MACEs-were comparable between groups. No thrombosis events were reported.DCB treatment of de novo SVD was superior to POBA with lower 9-month in-segment LLL. The rates of clinical events were comparable between the two devices.© 2022 Wiley Periodicals LLC.

语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 3 区 医学
小类 | 4 区 心脏和心血管系统
最新[2025]版：
大类 | 3 区 医学
小类 | 3 区 心脏和心血管系统
JCR分区：
出版当年[2021]版：
Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
最新[2023]版：
Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者单位： [1]Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China. [2]National Clinical Research Center for Interventional Medicine, Shanghai, China.
共同第一作者：
通讯作者：
通讯机构： [1]Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China. [2]National Clinical Research Center for Interventional Medicine, Shanghai, China. [*1]Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital Fudan University, National Clinical Research Center for Interventional Medicine, 180 Fenglin Rd, Shanghai 200032, China.
推荐引用方式(GB/T 7714)：
Qian Juying,Wu Yizhe,Li Chenguang,et al.Drug-coated balloon for the treatment of small vessel disease: 9 months of angiographic results and 12 months of clinical outcomes of the PEPCAD China SVD study[J].CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS.2023,101(1):33-43.doi:10.1002/ccd.30472.
APA：
Qian Juying,Wu Yizhe,Li Chenguang,Yin Jiasheng,Fu Guosheng...&Ge Junbo.(2023).Drug-coated balloon for the treatment of small vessel disease: 9 months of angiographic results and 12 months of clinical outcomes of the PEPCAD China SVD study.CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS,101,(1)
MLA：
Qian Juying,et al."Drug-coated balloon for the treatment of small vessel disease: 9 months of angiographic results and 12 months of clinical outcomes of the PEPCAD China SVD study".CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS 101..1(2023):33-43

相关文献

[1]A risk score to predict postdischarge bleeding among acute coronary syndrome patients undergoing percutaneous coronary intervention: BRIC-ACS study [2]Application of the SYNTAX score in interventional cardiology A systematic review and meta-analysis [3]Antithrombotic Therapy With Ticagrelor in Atrial Fibrillation Subjects After Percutaneous Coronary Intervention [4]Safety and efficacy of zotarolimus- eluting stents in the treatment of diabetic coronary lesions in Chinese patients: The RESOLUTE- DIABETES CHINA Study [5]准分子激光冠状动脉斑块消蚀术治疗复杂冠状动脉病变的临床观察 [6]经左侧桡动脉途径行急性心肌梗死急诊介入治疗的效果 [7]A randomized comparison of a novel iopromide-based paclitaxel-coated balloon Shenqi versus SeQuent Please for the treatment of in-stent restenosis [8]C-Reactive Protein and Inflammatory Cytokines during Percutaneous Coronary Intervention [9]The efficacy and safety of P2Y12 inhibitor monotherapy in patients after percutaneous coronary intervention [10]Relationship Between β-Blocker Therapy at Discharge and Clinical Outcomes in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

资源点击量：590 今日访问量：0 总访问量：442 更新日期：2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）